Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04218123 · ClinicalTrials.gov registry record · Phase 2

Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes

A Phase 2 study of Meniere Disease, sponsored by Medical University of South Carolina.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT04218123 is a Phase 2 study of Meniere Disease that has completed, run by Medical University of South Carolina. The registered enrollment target is 40 participants, below the 103-participant average among 3 other Meniere Disease trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04218123, a Phase 2 study of Meniere Disease, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

As of yet, the cause of Meniere's disease is uncertain and there is no cure. Given the lack of high level evidence for treatments, we seek to perform a randomized, placebo-controlled, double-blind, crossover, pilot trial of venlafaxine for treating Meniere's disease. Venlafaxine is a safe and well-tolerated medication. It has never been trialed in Meniere's disease, but there is evidence that it could be effective in helping with vertigo attacks and other aspects of the disorder.

Conditions Studied

Interventions

  • DRUG Placebo oral tablet
  • DRUG Venlafaxine

Study Locations (1)

South Carolina

  • Medical Univeristy of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2020-02-05
Est. Completion 2023-09-14
Phase Phase 2

What the Registry Record Tells You About NCT04218123

The ClinicalTrials.gov registry entry for NCT04218123 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 3 other Meniere Disease trials with a reported enrollment target (61% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Meniere Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral tablet is the first listed.

NCT04218123 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.

Frequently Asked Questions

What is clinical trial NCT04218123 about?

NCT04218123 is a clinical study titled "Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes". As of yet, the cause of Meniere's disease is uncertain and there is no cure. Given the lack of high level evidence for treatments, we seek to perform a randomized, placebo-controlled, double-blind, crossover, pilot trial of venlafaxine for treating Meniere's disease. Venlafaxine is a safe and well-t...

What is the current status of trial NCT04218123?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2020-02-05. Estimated completion is 2023-09-14.

What conditions does trial NCT04218123 study?

This clinical trial studies the following conditions: Meniere Disease.

What interventions are being tested in trial NCT04218123?

The interventions under investigation include: Placebo oral tablet (DRUG), Venlafaxine (DRUG).

Who is sponsoring clinical trial NCT04218123?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04218123 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Meniere Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.